Despite the failure of docking with SRSF1, the docking of vindesine and ON-01910 with HSP90AA1 and HSPA9 tentatively validated the feasibility of these drugs binding to the hub genes, indicating that vindesine and ON-01910 may be disease-specific agents of ICM and COVID-19. The gene discussed is HSPA9; the disease is COVID-19.